Login to Your Account


HONG KONG – South Korean startup Orum Therapeutics Inc. has a shot at effectively blocking RAS gene function with an innovative technology co-developed with Ajou University in South Korea and last week raised $8 million in a series A round to advance work in oncology indications.

SHANGHAI – Inventisbio Inc., has emerged from stealth, nabbing $19 million in series B financing from health care venture financiers Orbimed and Lilly Asia Ventures (LAV).

BUENOS AIRES, Argentina – Andes Biotechnologies SA, a cancer drug company from Santiago, Chile, is planning to cement its presence in the U.S. as it begins to emerge from stealth mode.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: